孤儿药品标签扩展:对随后的罕见和常见指示批准的分析
Kathleen L Miller1, Michael Lanthier2
1Kathleen L. Miller (kathleen.miller@hhs.gov), Department of Health and Human Services, Washington, D.C.
Health affairs (Project Hope)
|January 8, 2024
概括
孤儿药物法案鼓励罕见疾病药物开发. 一项研究发现,20%的批准的孤儿药物针对罕见和常见疾病,影响潜在的政策变化.
科学领域:
- 药物经济学 药物经济学
- 药物政策 药物政策
- 罕见疾病研究 罕见疾病研究
背景情况:
- 1983年"孤儿药物法案" (ODA) 旨在鼓励开发用于罕见疾病的药物.
- 最近的政策讨论质疑ODA的激励措施,因为人们担心对常见疾病和多种适应症的批准.
研究的目的:
- 调查ODA批准的孤儿药物的批准途径和适用情况.
- 分析仅用于罕见疾病,罕见和常见疾病以及儿科罕见疾病批准的孤儿药物的流行情况.
主要方法:
- 对1990年至2022年间的孤儿药批准数据的分析.
- 对药物指示扩展的检查,包括对儿科患者群体的扩展.
- 对最销的孤儿药物的收入数据的评估.
主要成果:
- 在1990年至2022年期间,批准了491种新的孤儿药物.
- 20%的这些孤儿药物获得了对罕见疾病和常见疾病的批准.
- 10%的孤儿药物获得了随后的批准,用于儿科罕见病人群.
结论:
- 很大一部分孤儿药物被批准用于常见疾病,这引发了关于ODA重点的问题.
- 修改官方发展援助的激励措施可能会减少用于儿科罕见病的孤儿药物的开发.
更多相关视频
相关概念视频
Prescription, Nonprescription and Orphan Drugs
734
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
734
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Pharmacovigilance
835
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
835
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drug Nomenclature
1.8K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.8K
Analysis of Population Pharmacokinetic Data
263
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
263


